IR-arkiv | Affibody Medical AB

Affibody Medical Investor Relations

Categories:

Navigation:

Regulatory

February 19, 2026

Affibody Signs Letter of Intent with SHINE Technologies for Supply of Lutetium-177

Stockholm, Sweden, February 19, 2026. Affibody AB (“Affibody”) today announced that a Letter of Intent (LOI) has been signed with SHINE Technologies, LCC (“SHINE”) as an additional supplier of...

Regulatory

February 17, 2026

Affibody’s licensee Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement

Stockholm, Sweden, February 17, 2026. Affibody’s licensee Rallybio Corporation (Rallybio) has today announced positive results from its Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) clinical study evaluating RLYB116, an innovative, once-weekly,...

Regulatory

January 20, 2026

Affibody Carries Out Fully Guaranteed Rights Issue of SEK 307 Million

Stockholm, Sweden, January 20, 2026. Affibody Medical AB (publ) (“Affibody”) today announced that the Board of Directors, with authorization from the annual general meeting on May 27, 2025, has...

Regulatory

December 16, 2025

Affibody Accelerates Phase 1 Study with ABY-271 Following Initial Patient Data

Stockholm, Sweden, December 16, 2025. Affibody AB (“Affibody”) today announced that the Trial Review Committee (TRC) has recommended to advance the Phase I clinical study with the Radioligand Therapy...

Regulatory

October 24, 2025

Positive 52-week Phase 2b/3 Data of Izokibep in Psoriatic Arthritis to be Presented at ACR Convergence 2025

Solna, Sweden, October 24, 2025. Affibody AB (“Affibody”) today announced that positive 52-week data from a global Phase 2b/3 study of izokibep in psoriatic arthritis (PsA) will be presented...

Regulatory

October 21, 2025

First Patients Enrolled in Diagnostic Phase 2 Imaging Study with Affibody’s PET Imaging Agent Tezatabep Matraxetan in Metastatic Breast Cancer

Solna, Sweden, October 21, 2025. Affibody AB (“Affibody”) today announced the enrollment of the first patients in a diagnostic Phase 2 imaging study evaluating tezatabep matraxetan, the company’s PET...

Regulatory

October 7, 2025

First Patient Dosed in Phase 1 Clinical Study with Affibody’s Radiotherapeutic ABY-271 in HER2-positive Metastatic Breast Cancer

Solna, Sweden, October 7, 2025. Affibody AB (“Affibody”) today announced that the first patient has been dosed in a Phase 1 clinical study with the company’s radiotherapeutic candidate ABY-271...

Regulatory

September 30, 2025

Affibody Announces Broad Scientific Progress at EANM 2025

Solna, Sweden, September 30, 2025. Affibody AB (“Affibody”) today announced it will have substantial scientific presence at the 2025 Congress of the European Association of Nuclear Medicine (EANM), taking...

Regulatory

September 19, 2025

Positive 16-week Phase 3 Data of Izokibep in Hidradenitis Suppurativa Presented at EADV 2025

Solna, Sweden, September 19, 2025. Affibody AB (“Affibody”) today announced positive 16-week data from a global Phase 3 study of izokibep in hidradenitis suppurativa (HS) that was presented at...